2010年1月至今,引用Selleck产品的顶级学术期刊文献已达 237 篇!

新产品

目录号 产品名 Target Pathway 产品描述
S8854 JNJ-38877618(OMO-1) c-Met Protein Tyrosine Kinase JNJ-38877618 (OMO-1) is a potent, highly selective, orally bioavailable MET kinase inhibitor with binding affinity (Kd) of 1.4 nM and enzyme inhibitory activity against wt and M1268T mutant MET (2 and 3 nM IC50).
S8297 ARV-825 Epigenetic Reader Domain Epigenetics ARV-825 is a BRD4 Inhibitor that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 and sustained down-regulation of MYC.
S8722 ICEC0942 (CT7001) CDK Cell Cycle ICEC0942 (CT7001) is a new, orally bioavailable CDK7 inhibitor with an IC50 of 40nM. The IC50 values for CDK1, CDK2, CDK5 and CDK9 were 45-, 15-, 230- and 30-fold higher.
S8735 BI-3812 Bcl-6 Apoptosis BI-3812 is a highly potent and efficacious BCL6 inhibitor probe compound with an IC50 less than 3 nM.
S8826 BAY-293 Rho Cell Cycle BAY-293 selectively inhibits the KRAS-SOS1 interaction with an IC50 of 21 nM.
S8568 G1T38 CDK Cell Cycle Lerociclib (G1T38) is a novel, potent, selective, and orally bioavailable CDK4/6 inhibitor with IC50 values of 0.001 μM, 0.002 μM and 0.028 μM for CDK4, CDK6 and CDK9 respectively.
S8842 BAY-218 AhR Metabolism BAY-218 is a potent and selective small-molecule AhR inhibitor, inhibiting AhR nuclear translocation, dioxin response element (DRE)-luciferase reporter expression and AhR-regulated target gene expression induced by both exogenous and endogenous AhR ligands.
S8676 Glumetinib (SCC244) c-Met Protein Tyrosine Kinase Glumetinib (SCC244) is a potent and highly selective c-Met inhibitor with an IC50 of 0.42 ± 0.02 nmol/L. Glumetinib has greater than 2,400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, and TyrO3.